Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Climb Bio, Inc. (CLYM : NSDQ)

• Company Description    Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass. Number of Employees: 18

• Price / Volume Information    Yesterday's Closing Price: $1.35 Daily Weekly Monthly 20 Day Moving Average: 378,408 shares Shares Outstanding: 67.58 (millions) Market Capitalization: $91.23 (millions) Beta: -0.13 52 Week High: $9.21 52 Week Low: $1.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.47% 1.52% 12 Week 7.14% -9.88% Year To Date -25.00% -29.76%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 20 William Street Suite 145 - Wellesley Hills,MA 02481 USA ph: 866-857-2596 fax: - investorrelations@climbbio.com http://www.eliemtx.com

• General Corporate Information    Officers Aoife Brennan - President and Chief Executive Officer Douglas E. Williams - Chairman Brett Kaplan - Chief Operating Officer Emily Pimblett - Chief Accounting Officer Andrew Levin - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28658R106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 67.58 Most Recent Split Date: (:1) Beta: -0.13 Market Capitalization: $91.23 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.90 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.47 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -416.67% vs. Previous Quarter: -138.46% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -43.95 12/31/24 - -38.93 ROA 06/30/25 - - 03/31/25 - -42.94 12/31/24 - -38.15 Current Ratio 06/30/25 - - 03/31/25 - 14.25 12/31/24 - 31.41 Quick Ratio 06/30/25 - - 03/31/25 - 14.25 12/31/24 - 31.41 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 2.86 12/31/24 - 3.15 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©